Onyx Biotec Ltd
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
- Market Cap ₹ 95.8 Cr.
- Current Price ₹ 52.8
- High / Low ₹ 97.4 / 48.9
- Stock P/E 19.1
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 12.0 %
- ROE 14.1 %
- Face Value ₹ 10.0
Pros
Cons
- Company might be capitalizing the interest cost
- Debtor days have increased from 73.3 to 104 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|
44.86 | 39.49 | 53.75 | 60.01 | |
39.09 | 34.99 | 45.42 | 49.39 | |
Operating Profit | 5.77 | 4.50 | 8.33 | 10.62 |
OPM % | 12.86% | 11.40% | 15.50% | 17.70% |
0.12 | 0.11 | 0.13 | 1.08 | |
Interest | 0.65 | 0.57 | 2.16 | 2.63 |
Depreciation | 1.45 | 1.49 | 2.25 | 2.67 |
Profit before tax | 3.79 | 2.55 | 4.05 | 6.40 |
Tax % | 11.61% | 27.45% | 25.19% | |
3.35 | 1.84 | 3.03 | 5.02 | |
EPS in Rs | 5.68 | 3.12 | 2.27 | 3.76 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 36% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 64% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 5.90 | 5.90 | 13.32 | 13.32 |
Reserves | 10.47 | 12.30 | 11.56 | 14.95 |
12.25 | 29.23 | 30.78 | 30.17 | |
8.22 | 11.30 | 18.47 | 19.35 | |
Total Liabilities | 36.84 | 58.73 | 74.13 | 77.79 |
17.23 | 42.50 | 43.48 | 41.91 | |
CWIP | 4.02 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 |
15.59 | 16.23 | 30.65 | 35.88 | |
Total Assets | 36.84 | 58.73 | 74.13 | 77.79 |
Cash Flows
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
0.49 | 1.96 | 1.52 | |
-5.78 | -22.68 | -3.15 | |
5.20 | 16.43 | 3.09 | |
Net Cash Flow | -0.09 | -4.30 | 1.46 |
Ratios
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 68.51 | 46.95 | 104.37 |
Inventory Days | 41.98 | 109.92 | 92.94 |
Days Payable | 59.46 | 120.16 | 140.83 |
Cash Conversion Cycle | 51.03 | 36.71 | 56.48 |
Working Capital Days | 65.09 | 51.39 | 86.11 |
ROCE % | 8.23% | 12.05% |
Documents
Announcements
-
General Updates
24 April 2025 - Onyx Biotec signs agreement with Galpha Labs for Dry Powder Injection manufacturing.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 April 2025 - SEBI Reg 74(5) certificate for quarter ended March 31, 2025
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
9 April 2025 - Non-applicability of SEBI corporate governance provisions due to SME listing
-
Press Release
8 April 2025 - Agreement with Galpha Labs for manufacturing Dry Powder Injection.
-
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
29 March 2025 - ONYX BIOTEC LIMITED has informed about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
Annual reports
No data available.
Business Overview:[1]
OBL is associated with the healthcare segment and is a supplier of sterile pharmaceutical products to major corporations. Presently, OBL manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. It provides end-to-end product development and manufacturing solutions and its services
also include preparation and filing of regulatory dossiers in the Indian and global markets.